Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
Immunogen sequence: AFYDNCRRLR CFPQPPRRNW FWGHQGMVNP TEEGMRVLTQ LVATYPQGFK VWMGPISPLL SLCHPDIIRS VINASAAIAP K; Positive Samples: LO2, HepG2, 293T; Cellular Location: Endoplasmic reticulum membrane, Microsome membrane, Peripheral membrane protein
CYP4F isoforms are involved in the oxidation of important cellular mediators, such as leukotriene B4 (LTB4) and prostaglandins. CYP4F2 catalyzes omega-hydroxylation of LTB4 to a less potent proinflammatory eicosanoid, 20-OH-LTB4 as well as arachidonic acid. CYP4F2 is expressed in liver and kidney. Its expression is repressed by peroxisomal proliferators and induced by retinoic acid. X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disorder biochemically characterized by elevated levels of very long-chain fatty acids (VLCFA). CYP4F2 participates in the omega-hydroxylation of VLCFAs, which may provide an alternative mode of treatment for X-ALD patients.
仅用于科研。不用于诊断过程。未经明确授权不得转售。